OJIM  Vol.5 No.4 , December 2015
Influence of Antiretroviral Therapy on the Metabolic Profile of People Living with HIV Followed at University Hospital, Cotonou, Benin
Abstract: Introduction: Since the advent of antiretroviral therapy, the vital prognosis of people living with HIV (PLWHA) has improved significantly. However, the risk of metabolic complications is high, thus making the bed of cardiovascular disease. Our objective was to compare the prevalence of metabolic abnormalities among PLWHA receiving ARVs to that observed in those who are not treated. Methods: We conducted a cross-sectional study (January to April 2010) at the PLWHA ambulatory care center of national university hospital (CNHU-Hubert K. Maga) in Cotonou, Bénin. We recruited 420 PLWHA (210 treated for at least 6 months and 210 untreated). We determined the prevalence of metabolic syndrome (MS) defined by the criteria of NCEP-ATP III, and the prevalence of abnormal glucose and lipid, and lipodystrophy. Association between metabolic syndrome and ARVs used was analyzed by binomial regression. Confidence intervals were calculated at 95% and 5% alpha level. Results: The prevalence of MS was 16% (18% of patients treated vs. 13% of non-treated, p = 0.18). That of hyperglycemia was 18% (30% of patients treated vs. 6% of untreated; p < 0.001) and of diabetes 7% (12% of patients treated vs 2% of untreated; p < 0.0001). The total cholesterol prevalence was 29% (44% of treated vs 13% of untreated; p <0.02). That of lipodystrophy in 210 patients was 29% (lipoatrophy16%, lipohypertrophy 8%, mixed form 6%). Factors associated with metabolic syndrome were age, hypertension, diabetes (personal or family), BMI, exposure to stavudine (OR = 1.59 [1.02 to 2.47], p = 0.04) and indinavir booted with ritonavir (OR = 2.23 [1.11 to 4 46], p = 0.02). Conclusion: The metabolic abnormalities are more common in PLWHA treated with ARVs. Preventing these anomalies should be made to the initiation of antiretroviral therapy and during the therapeutic monitoring.
Cite this paper: Zannou, D. , Azon-Kouanou, A. , Ahomadegbe, M. , Agbodande, K. , Akakpo, J. , Dovonou, C. , Amoussou-Guenou, K. , Tchabi, Y. , Ade, G. and Houngbe, F. (2015) Influence of Antiretroviral Therapy on the Metabolic Profile of People Living with HIV Followed at University Hospital, Cotonou, Benin. Open Journal of Internal Medicine, 5, 106-114. doi: 10.4236/ojim.2015.54015.

[1]   Signorini, D.J., Monteiro, M.C., Andrade Mde, F., Signorini, D.H. and Eyer-Silva Wde, A. (2012) What Should We Know about Metabolic Syndrome and Lipodystrophy in AIDS? Revista da Associação Médica Brasileira, 58, 70-75.

[2]   Niakara, A., Drabo, Y.J., Kambire, Y., Nebie, L.V.A., Kabore, N.J.P. and Simon, F. (2002) Atteintes cardio-vasculaires et infection par le VIH : étude de 79 cas au CHN de Ouagadougou (Burkina Faso). Bulletin de la Société de Pathologie Exotique, 95, 23-26.

[3]   Friis-Moller, N., Sabin, C.A. and Weber, R., The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. The New England Journal of Medicine, 349, 1993-2003.

[4]   May, T., Lewden, C., Bonnet, F., Heripret, L., Bevilacqua, S., Jougla, E., et al. (2004) Causes et caractéristiques des décès des patients infectés par le VIH-1 en succès immuno-virologique, sous traitement antirétroviral. La Presse Médicale, 33, 1487-1492.

[5]   Zannou, D.M., Denoeud, L., Lacombe, K., Amoussou-Guenou, D., Bashi, J., Akakpo, J., et al. (2009) Incidence of Lipodystrophy and Metabolic Disorders in Patients Starting Non-Nucleoside Reverse Transcriptase Inhibitors in Benin. Antiviral Therapy, 14, 371-380.

[6]   Samaras, K., Wand, H., Law, M., Emery, S., Cooper, D. and Carr, A. (2007) Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with Insulin Resistance, Disturbed Body Fat Compartmentalization, Elevated C-Reactive Protein, and Hypoadiponectinemia. Diabetes Care, 30, 113-119.

[7]   Guira, O., Tiéno, H., Diendéré, A.E., Sagna, Y., Diallo, I., Yaméogo, B., et al. (2015) Features of Metabolic Syndrome and Its Associated Factors during Highly Active Antiretroviral Therapy in Ouagadougou (Burkina Faso). Journal of the International Association of Providers of AIDS Care (JIAPAC), 1-5.

[8]   Ayodele, O.E., Akinboro, A.O., Akinyemi, S.O., Adepeju, A.A., Akinremi, O.A., Alao, C.A. and Popoola, A.A. (2012) Prevalence and Clinical Correlates of Metabolic Syndrome in Nigerians Living with Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome. Metabolic Syndrome and Related Disorders, 10, 373-379.

[9]   Martinez, E., Domingo, P., Galindo, M.J., Milinkovic, A., Arroyo, J.A., Baldovi, F., et al. (2004) Risk of Metabolic Abnormalities in Patients Infected with HIV Receiving Antiretroviral Therapy That Contains Lopinavir-Ritonavir. Clinical Infectious Diseases, 38, 1017-1023.

[10]   Biron, C., Bobin-Dubigeon, C., Leport, C., Piroth, L., Perré, P., Bard, J.M. and Raffi, F. (2008) Syndrome métabolique chez les patients VIH sous HAART depuis 1 an à 4 ans : Etude SYMET. Médecine et Maladies Infectieuses, 38, S172.

[11]   Kalyanasundaram, A.P., Jacob, S.M., Hemalatha, R. and Sivakumar, M.R. (2012) Prevalence of Lipodystrophy and Dyslipidemia among Patients with HIV Infection on Generic ART in Rural South India. Journal of the International Association of Physicians in AIDS Care, 11, 329-334.

[12]   Murata, H., Hruz, P.W. and Muechler, M. (2002) The Mechanisms of Insulin Resistance Caused by HIV Protease Inhibitor Therapy. The Journal of Biological Chemistry, 275, 20251-20254.

[13]   Mooser, V. and Caar, A. (2001) Antiretroviral Therapy-Associated Hyperlipidaemia in HIV Disease. Current Opinion in Lipidology, 12, 313-319.

[14]   Riddle, T., Kuhel, D., Woollett, L., Fichtenbaum, C. and Hui, D.Y. (2001) HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element Binding Proteins in the Nucleus. The Journal of Biological Chemistry, 276, 37514-37519.

[15]   Blanco, F., San Román, J., Vispo, E., Lopez, M., Salto, A., Abad, V. and Soriano, V. (2010) Management of Metabolic Complications and Cardiovascular Risk in HIV-Infected Patients. AIDS Reviews, 12, 231-241.

[16]   Mondy, K.E., de las Fuentes, L. and Waggoner, A. (2008) Insulin Resistance Predicts Endothelial Dysfunction and Cardiovascular Risk in HIV-Infected Persons on Long-Term Highly Active Antiretroviral Therapy. AIDS, 22, 849-856.

[17]   Zannou, D.M., Tchabi, Y., Ahomadégbé, C., Akakpo, J., Azon-Kouanou, A., Adé, G., et al. (2013) Cardiovascular Risk among People Living with HIV at the Academic Hospital of Cotonou, Bénin. Médecined’Afrique Noire, 60, 419-426.

[18]   Yoon Cecilia, J. (2005) Le diabète chez les personnes atteintes du VIH. Diabetesvoice, 50, 13-15.

[19]   Bakari, A.G., Sani-Bello, F., Shehu, M.S., Mai, A., Ibrahim, S.A. and Ibrahim, I.L. (2007) Antiretroviral Therapy Induced Diabetes in a Nigerian. African Health Sciences, 7, 133-135.

[20]   Leitner, J.M., Pernerstorfer-Schoen, H., Weiss, A., Schindler, K., Rieger, A. and Jilma, B. (2006) Age and Sex Modulate Metabolic and Cardiovascular Risk Markers of Patients after 1 Year of Highly Active Antiretroviral Therapy (HAART). Atherosclerosis, 187, 177-185.

[21]   de Saint Martin, L., Pasquier, E., Roudaut, N., Vandhuick, O., Vallet, S., Bellein, V. and Bressollette, L. (2008) Metabolic Syndrome : A Major Risk Factor for Atherosclerosis in HIV-Infected Patients (SHIVA Study). La Presse Médicale, 37, 579-584.

[22]   Dube, M.P., Parker, R.A. and Tebas, P. (2005) Glucose Metabolism, Lipid, and Body Fat Changes in Antiretroviral- Naive Subjects randomized to Nelfinavir or Efavirenz Plus Dual Nucleosides. AIDS, 19, 1807-1818.

[23]   Serfaty, L., Mathurin, P., Cadranel, J.F. and Tran, A. (2007) Alcool, syndrome métabolique et obésité: Impact sur la réponse au traitement. Gastroentérologie Clinique et Biologique, 31, 40-43.

[24]   Poynard, T., Bedossa, P. and Opolon, P., for the OBSVIR, METAVIR, CLINIVIR, and DOSVIR Groups (1997) Natural History of Liver Fibrosis Progression in Patients with Chronic Hepatitis C. Lancet, 349, 825-832.